Teacher Retirement System of Texas Has $337,000 Stake in NeoGenomics, Inc. (NASDAQ:NEO)

Teacher Retirement System of Texas trimmed its holdings in NeoGenomics, Inc. (NASDAQ:NEOFree Report) by 33.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,839 shares of the medical research company’s stock after selling 10,555 shares during the period. Teacher Retirement System of Texas’ holdings in NeoGenomics were worth $337,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its stake in NeoGenomics by 4.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,046,565 shares of the medical research company’s stock valued at $16,933,000 after acquiring an additional 41,794 shares during the period. Lisanti Capital Growth LLC acquired a new position in shares of NeoGenomics during the fourth quarter worth about $3,445,000. Natixis Advisors L.P. boosted its position in shares of NeoGenomics by 103.4% during the fourth quarter. Natixis Advisors L.P. now owns 39,360 shares of the medical research company’s stock worth $636,000 after buying an additional 20,010 shares during the period. White Pine Capital LLC acquired a new position in shares of NeoGenomics during the fourth quarter worth about $261,000. Finally, Semanteon Capital Management LP acquired a new position in shares of NeoGenomics during the fourth quarter worth about $1,132,000. 98.50% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Price Performance

NASDAQ:NEO opened at $14.13 on Wednesday. The company has a quick ratio of 7.22, a current ratio of 7.48 and a debt-to-equity ratio of 0.58. The stock’s 50 day moving average price is $14.72 and its two-hundred day moving average price is $16.04. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -21.41 and a beta of 1.12. NeoGenomics, Inc. has a 12-month low of $11.03 and a 12-month high of $21.22.

NeoGenomics (NASDAQ:NEOGet Free Report) last posted its earnings results on Tuesday, April 30th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). NeoGenomics had a negative net margin of 13.79% and a negative return on equity of 3.54%. The firm had revenue of $156.24 million during the quarter, compared to analyst estimates of $149.82 million. On average, analysts anticipate that NeoGenomics, Inc. will post -0.21 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Needham & Company LLC reduced their price objective on NeoGenomics from $24.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. BTIG Research dropped their target price on NeoGenomics from $23.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, May 2nd. The Goldman Sachs Group upped their target price on NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Craig Hallum assumed coverage on NeoGenomics in a report on Wednesday, May 1st. They set a “buy” rating and a $26.00 target price on the stock. Finally, Piper Sandler upped their target price on NeoGenomics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, NeoGenomics has a consensus rating of “Moderate Buy” and an average target price of $19.78.

Read Our Latest Report on NeoGenomics

NeoGenomics Profile

(Free Report)

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

Further Reading

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEOFree Report).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.